The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021
- PMID: 35598097
- PMCID: PMC9348424
- DOI: 10.5694/mja2.51542
The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021
Keywords: COVID-19.
Conflict of interest statement
Danielle Wurzel received honoraria by Merck for a presentation not related to this study. Helen Marshall received funding from GlaxoSmithKline, Pfizer, and Sanofi‐Pasteur for investigator‐led and sponsored vaccine trials (paid to the University of Adelaide). Britta von Ungern‐Sternberg has received funding from the Stan Perron Charitable Foundation not related to this study.
Figures


References
-
- Gidding HF, Machalek DA, Hendry AJ, et al. Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020. Med J Aust 2021; 214: 179‐185. https://www.mja.com.au/journal/2021/214/4/seroprevalence‐sars‐cov‐2‐spec... - PMC - PubMed
-
- Australian Bureau of Statistics . Estimated resident Aboriginal and Torres Strait Islander and non‐Indigenous populations, states and territories; 30 June 2016. 31 Aug 2018. https://www.abs.gov.au/statistics/people/aboriginal‐and‐torres‐strait‐is... (viewed June 2021).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous